Efficacy of repetitive transcranial magnetic stimulation for Tourette syndrome: A systematic review and meta-analysis

Hsu, Chih‐Wei; Wang, Liang‐Jen; Lin, Pao‐Yen

doi:10.1016/j.brs.2018.06.002

Cited by 33 publications

(26 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Small‐scale, open‐label studies provide valuable contributions to the investigation of the therapeutic use of rTMS, though the lack of a sham control is an important limitation to consider. To date, two small‐scale, sham‐controlled studies have been published using the SMA as a stimulation site, both of which revealed strong placebo effects 5 . Yet, numerous methodological differences between this work and existing open‐label studies limits the strength of conclusions which can be drawn.…”

mentioning

confidence: 86%

“…To date, two small-scale, sham-controlled studies have been published using the SMA as a stimulation site, both of which revealed strong placebo effects. 5 Yet, numerous methodological differences between this work and existing open-label studies limits the strength of conclusions which can be drawn.…”

mentioning

confidence: 88%

“…Tics significantly reduced for all participants over the course of the study, a finding that corroborates reports from several small-scale, open-label trials. 5 The authors also endeavoured to measure physiological change using single/paired-pulse TMS and magnetic resonance spectroscopy. This approach has the potential to reveal important biomarkers of change; however, in this instance few statistically significant differences were found, likely owing to the small sample size.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Repetitive transcranial magnetic stimulation and Tourette syndrome: new findings and future directions

Dyke

2021

Develop Med Child Neuro

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 86%

mentioning

confidence: 88%

mentioning

confidence: 99%

See 1 more Smart Citation

Repetitive transcranial magnetic stimulation and Tourette syndrome: new findings and future directions

Dyke

2021

Develop Med Child Neuro

View full text Add to dashboard Cite

show abstract

“…For instance, highfrequency (excitatory) rTMS has been used to stimulate underactive left dorsolateral prefrontal cortex (DLPFC) in treatment-resistant depression, 11 while low-frequency (inhibitory) rTMS has been used to downregulate excessive activity in left auditory cortex in schizophrenia 12 and supplementary motor area (SMA) in Tourette's disorder. 13 Importantly, rTMS also influences broader brain networks that involve the stimulated region, 14 15 and this is thought to contribute to its clinical efficacy. Here we will stimulate the right temporoparietal junction (rTPJ), a key node for social cognition, which is a typical area of difficulty among individuals with ASD.…”

Section: Strengths and Limitations Of This Studymentioning

confidence: 99%

Repetitive transcranial magnetic stimulation (rTMS) in autism spectrum disorder: protocol for a multicentre randomised controlled clinical trial

et al. 2021

View full text Add to dashboard Cite

IntroductionThere are no well-established biomedical treatments for the core symptoms of autism spectrum disorder (ASD). A small number of studies suggest that repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation technique, may improve clinical and cognitive outcomes in ASD. We describe here the protocol for a funded multicentre randomised controlled clinical trial to investigate whether a course of rTMS to the right temporoparietal junction (rTPJ), which has demonstrated abnormal brain activation in ASD, can improve social communication in adolescents and young adults with ASD.Methods and analysisThis study will evaluate the safety and efficacy of a 4-week course of intermittent theta burst stimulation (iTBS, a variant of rTMS) in ASD. Participants meeting criteria for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition ASD (n=150, aged 14–40 years) will receive 20 sessions of either active iTBS (600 pulses) or sham iTBS (in which a sham coil mimics the sensation of iTBS, but no active stimulation is delivered) to the rTPJ. Participants will undergo a range of clinical, cognitive, epi/genetic, and neurophysiological assessments before and at multiple time points up to 6 months after iTBS. Safety will be assessed via a structured questionnaire and adverse event reporting. The study will be conducted from November 2020 to October 2024.Ethics and disseminationThe study was approved by the Human Research Ethics Committee of Monash Health (Melbourne, Australia) under Australia’s National Mutual Acceptance scheme. The trial will be conducted according to Good Clinical Practice, and findings will be written up for scholarly publication.Trial registration numberAustralian New Zealand Clinical Trials Registry (ACTRN12620000890932).

show abstract

“…For example, transcranial magnetic stimulation is a form of non-invasive brain stimulation that can change brain activity and function in parts of the brain (Klomjai et al, 2015). It has proven effective for individuals with treatment-resistant Major Depressive Disorder (Gaynes et al, 2014;McClintock et al, 2018) and is a promising treatment for many other psychiatric and neurodevelopmental disorders (Cirillo et al, 2019;Hsu et al, 2018;Lusicic et al, 2018). Thus, combining neuroimaging techniques (like magnetic resonance imaging and spectroscopy) with neurostimulation paradigms could transform our understanding of eating disorders.…”

Section: Funding Agencymentioning

confidence: 99%

Food for thought: A dissonance between healthcare utilization costs and research funding for eating disorders in Canada

Stone¹,

Dimitropoulos²,

MacMaster³

2021

Preprint

View full text Add to dashboard Cite

In this commentary, we present the premise that, in Canada, mental illness research specific to eating disorders is predominantly underfunded, and many Canadians are suffering the consequences of it. We highlight three main drivers underlying this issue: 1) the increasingly common yet potentially life-threatening nature of eating disorders, with an onset usually during adolescence; 2) the challenges and costs to treating eating disorders, with a discussion of current hospital-related costs across Canada; and 3) the glaring discrepancy between the money spent on eating disorder diagnoses/treatment and the funding dollars granted for eating disorder research in Canada (i.e. only $0.70 per affected Canadian in 2018). Research funding per affected individual for other psychiatric and neurodevelopmental conditions are used as comparisons (e.g. $50.17 per affected Canadian with schizophrenia). We suggest that it is time to revolutionize treatment for individuals with eating disorders and use our resources in a more efficient and effective manner, using current neuroimaging and neuromodulation methods as promising examples. We conclude by emphasizing the need for increased research funding in the field of eating disorders in Canada, as the current research-related investments hinder progress in developing neuroscientifically-sound treatments for these populations.

show abstract

Efficacy of repetitive transcranial magnetic stimulation for Tourette syndrome: A systematic review and meta-analysis

Cited by 33 publications

References 66 publications

Repetitive transcranial magnetic stimulation and Tourette syndrome: new findings and future directions

Repetitive transcranial magnetic stimulation and Tourette syndrome: new findings and future directions

Repetitive transcranial magnetic stimulation (rTMS) in autism spectrum disorder: protocol for a multicentre randomised controlled clinical trial

Food for thought: A dissonance between healthcare utilization costs and research funding for eating disorders in Canada

Contact Info

Product

Resources

About